Annals of hematology & oncology最新文献_第5页

Pembrolizumab in MSI-high Pancreatic Sarcomatoid Carcinoma Pembrolizumab在MSI高胰腺肉瘤样癌中的应用

Annals of hematology & oncology Pub Date : 2021-02-10 DOI: 10.26420/annhematoloncol.2021.1327

Mayrhofer K

{"title":"Pembrolizumab in MSI-high Pancreatic Sarcomatoid Carcinoma","authors":"Mayrhofer K","doi":"10.26420/annhematoloncol.2021.1327","DOIUrl":"https://doi.org/10.26420/annhematoloncol.2021.1327","url":null,"abstract":"We report the outcome of a patient with MSI-high metastatic pancreatic sarcomatoid carcinoma refractory to multiple lines of chemotherapy treated successfully with pembrolizumab. In November 2015, our patient presented with epigastric pain leading to radiologic workup. A lesion in the pancreas as well as liver metastasis were diagnosed; liver biopsy revealed a poorly differentiated sarcomatoid carcinoma. After having received every approved chemotherapy for pancreatic cancer his disease eventually progressed so that we reached out for novel therapeutic strategies. Because of the tumor being MSI high, treatment with pembrolizumab was commenced in May 2017. Clinical response with better overall quality of life was soon reported and repeated CT scans showed an ongoing partial response leading to a near complete remission in the latest scan obtained. Adverse events during the course of therapy included immune mediated arthralgia grade 1, colitis grade 2 and pneumonitis grade 1 which were managed by administration of glucocorticoids without interruption of immunotherapy. To our knowledge, this is the first case of a patient with MSI high metastatic sarcomatoid carcinoma of the pancreas successfully treated with immunotherapy for more than three years.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46893587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Annals of hematology & oncology Pub Date : 2021-02-10 DOI: 10.26420/annhematoloncol.2021.1326

Hernández Rivera JCH, Lizardi Gómez LF, Reyes Sánchez, Guerrero Soto J, R. Je, Muñoz Menjivar C, Venegas Vera AV, Camarillo Rosas C, Patiño Ortega R, Arenas Osuna J, Arenas Osuna J, Paniagua Sierra R

{"title":"Factors Related to the Presence of Anemia in Patients with Chronic Kidney Disease in Hemodialysis","authors":"Hernández Rivera JCH, Lizardi Gómez LF, Reyes Sánchez, Guerrero Soto J, R. Je, Muñoz Menjivar C, Venegas Vera AV, Camarillo Rosas C, Patiño Ortega R, Arenas Osuna J, Arenas Osuna J, Paniagua Sierra R","doi":"10.26420/annhematoloncol.2021.1326","DOIUrl":"https://doi.org/10.26420/annhematoloncol.2021.1326","url":null,"abstract":"Introduction: The prevalence of anemia in Chronic Kidney Disease (CKD) is high. However, little is known about the factors related to anemia in patients with chronic Hemodialysis (HD) in Mexico. Material and Methods: A cross-sectional study was conducted in adult patients with CKD undergoing HD in the northern area of Mexico City treated at the Mexican Institute of Social Security. Hemoglobin (Hb) and Hematocrit (Htc) levels, as well as clinical and biochemical factors associated with anemia, were evaluated. Results: Data was collected from 747 patients, obtaining a mean hemoglobin of 9.7 g/dl (IQR 8.4-10.9 g/dl). The group was divided into two using Hb <10.0 g/dl and >10.0 g/dl as cutoff limits. Fifty six percent of the patients had hemoglobin =10.0 g/dl. Hb level <10.0 g/dl were associated with DM (OR 1.49, IC 95% 1.06-2.10, p=0.001), hyperphosphatemia (OR 1.69, IC 95% 1.21-2.28, p=0.001), high calcium-phosphate product (OR 1.43, IC 95% 1.01-2.03, p=0.040) and iron deficiency (OR 1.95, IC 95% 1.38-2.75, p=0.001). Glomerulopathies (OR 0.44, IC 95% 0.22-0.90, p=0.026), female gender (OR 0.55, IC 95% 0.40-0.074, p=0.001) and erythropoietin administration (OR 0.57, IC 95% 0.39-0.82, p=0.002) were associated with hemoglobin ≥10 g/dl. Conclusion: The factors associated with Hb <10.0 g/dl were mineral-bone metabolism disorders and iron deficiency. The periodic evaluation of qualityof- care indicators of HD treatment, such anemia, are necessary to detect improvement opportunities.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48373487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Takotsubo Cardiomyopathy a Rare but Serious Complication of Treatment of Primary Central Nervous System Diffuse Large B Cell Lymphoma Takotsubo心肌病——原发性中枢神经系统弥漫性大B细胞淋巴瘤罕见但严重的并发症

Annals of hematology & oncology Pub Date : 2021-02-09 DOI: 10.26420/annhematoloncol.2021.1324

Zaucha Jm, S. A, Taszner M, Korzon Burakowska A

引用次数: 0

Additional Cytogenetic Aberrations Indicative of Poor Prognosis in AML with RUNX1/RUNX1T1 Rearrangement: Karyotype a Chromosomal Blueprint RUNX1/RUNX1T1重排AML预后不良的其他细胞遗传学异常：染色体蓝图的核型

Annals of hematology & oncology Pub Date : 2021-02-09 DOI: 10.26420/ANNHEMATOLONCOL.2021.1325

D. Shetty, E. Talker, H. Jain, S. Patil, P. Tembhare, N. Patkar, L. Nayak, M. Sengar

引用次数: 0

Severe Eosinophilia Associated with FIP1L1/PDGFRA Rearrangement Presenting with Yamaguchi Syndrome 严重嗜酸性粒细胞增多与FIP1L1/PDGFRA重排相关，表现为山口综合征

Annals of hematology & oncology Pub Date : 2021-02-01 DOI: 10.26420/ANNHEMATOLONCOL.2021.1323

Z. Aamir, F. Meraj, Hanif Hm

{"title":"Severe Eosinophilia Associated with FIP1L1/PDGFRA Rearrangement Presenting with Yamaguchi Syndrome","authors":"Z. Aamir, F. Meraj, Hanif Hm","doi":"10.26420/ANNHEMATOLONCOL.2021.1323","DOIUrl":"https://doi.org/10.26420/ANNHEMATOLONCOL.2021.1323","url":null,"abstract":"FIP1L1/PDGFRA is a rare genetic rearrangement, presenting most commonly as Chronic Eosinophilic Leukemia (CEL), but may also be associated with other myeloid and lymphoid neoplasms. The peripheral blood and bone marrow exhibit a striking eosinophilia, often associated with an increased number of mast cells on trephine biopsy. Tissue infiltration by eosinophils and release of cytokines from eosinophilic granules mediate multi-organ tissue damage. The tyrosine kinase inhibitor Imatinib has been shown to induce rapid and complete clinical and haematological responses in patients harboring the mutation. We present the case of a young patient with CEL associated with PDGFRA rearrangement, presenting with severe eosinophilia and evidence of multi-organ damage (cardiac, renal, endocrine and respiratory). The peripheral blood and bone marrow displayed a striking eosinophila, and FISH analysis for FIP1L1/PDGFRA revealed a positive fusion signal in 92% of the nuclei examined. Echocardiography showed left ventricular apical hypertrophy (Yamaguchi syndrome), which has previously not been reported in this subset of patients. He was managed with supportive care, along with low-dose imatinib (100mg/day initially), to which he achieved a rapid clinical and haematological response. Currently, five months from the initial diagnosis, he is doing well on low dose imatinib (100 mg) twice a week.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47814397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Fatal Case of Chronic Active EBV Infection 一例慢性活动性EB病毒感染致死病例

Annals of hematology & oncology Pub Date : 2021-01-12 DOI: 10.26420/ANNHEMATOLONCOL.2021.1322

D. Mehta, S. Deplano, E. Olavarría, P. Gaur, L. Bourantas

引用次数: 0

Off-Pump HeartMate 3® LVAD Implantation via Left Thoracotomy to Descending Aorta: Transition from Transaxillary Impella 5.0® LVAD 经左开胸至降主动脉的无泵心脏伴侣3®LVAD植入:从腋窝Impella 5.0®LVAD过渡

Annals of hematology & oncology Pub Date : 2021-01-01 DOI: 10.26420/annhematoloncol.2021.1352

L. R, A. A, Tuluca A, B. B, Bonita R, B. S, Hamshari Ya, Robbins T, Mossayebi Mh, S. l.

引用次数: 0

Cardiovascular Risk Management Recommendations for Patients with Chronic Myeloid Leukaemia who are Candidates for Ponatinib: Multidisciplinary Delphi Analysis 心血管风险管理建议慢性髓性白血病患者谁是Ponatinib候选人:多学科德尔菲分析

Annals of hematology & oncology Pub Date : 2021-01-01 DOI: 10.26420/annhematoloncol.2021.1354

Steegmann Jl, Zamorano Jl, P. Ja, Hernández-Boluda Jc, P. R, García-Gutierrez V, G. Jr, D. J, Roa-Chamorro R, Pardo A, A. A, F. E, López-Fernández T

引用次数: 0

Observation of Causes of Death from Sickle Cell Anemia in Niger 尼日尔镰状细胞性贫血死亡原因观察

Annals of hematology & oncology Pub Date : 2021-01-01 DOI: 10.26420/annhematoloncol.2021.1329

Djibrilla Almoustapha A, Maman Brah M, Chefou M, O. M., A. B, Lawali Issa H, M. S, Bade Mr, Issoufou F, B. S., Malam Abdou B, Adehossi Eo

{"title":"Observation of Causes of Death from Sickle Cell Anemia in Niger","authors":"Djibrilla Almoustapha A, Maman Brah M, Chefou M, O. M., A. B, Lawali Issa H, M. S, Bade Mr, Issoufou F, B. S., Malam Abdou B, Adehossi Eo","doi":"10.26420/annhematoloncol.2021.1329","DOIUrl":"https://doi.org/10.26420/annhematoloncol.2021.1329","url":null,"abstract":"Purpose: Improve the management of Major Sickle Cell Syndromes (SDM) by studying the circumstances in which patients affected by this disease die in Niger. Methods: This was a retrospective study of descriptive and analytical type in sickle cell patients followed at the National Sickle Cell Reference Center (CNRD) in Niamey with a follow-up file, who died during our study period, which was 9 years (January 1, 2010 to December 31, 2018). Results: During the study period, 6,465 sickle cell patients were followed up at the CNRD, 249 deaths were recorded, representing a frequency of 3.8%. There is a male predominance with a sex ratio of 1:3. The 0-15 age group was the most represented with 34.5% with an average age of 9.25 years. 34.1% of the patients came from a consanguineous marriage. Of the 249 deaths, 94% (n=234) were SS, 5.6% (n=14) were SC and 0.4% (n=1) was S/β. The majority of patients died at the time of registration, i.e. 58.25% (n=145 (SS=137. SC=8.)). 90.4% had died in a health-care facility. The main cause of death was anemia in 73.1% of cases. Conclusion: The management of sickle cell disease requires adequate preventive action to reduce the rate of early mortality.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69277558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concise Review: How are Red Blood Cells Born, How do they Live and Die? 简评:红细胞是如何产生的，它们是如何生存和死亡的?

Annals of hematology & oncology Pub Date : 2021-01-01 DOI: 10.26420/annhematoloncol.2021.1353

Vives Corrons J-L, Casafont Lb, Frasnedo Ef

引用次数: 0